Mouritzen, M.T.; Carus, A.; Ladekarl, M.; Meldgaard, P.; Nielsen, A.W.M.; Livbjerg, A.; Larsen, J.W.; Skuladottir, H.; Kristiansen, C.; Wedervang, K.;
et al. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy. Cancers 2021, 13, 4846.
https://doi.org/10.3390/cancers13194846
AMA Style
Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K,
et al. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy. Cancers. 2021; 13(19):4846.
https://doi.org/10.3390/cancers13194846
Chicago/Turabian Style
Mouritzen, Mette T., Andreas Carus, Morten Ladekarl, Peter Meldgaard, Anders W. M. Nielsen, Anna Livbjerg, Jacob W. Larsen, Halla Skuladottir, Charlotte Kristiansen, Kim Wedervang,
and et al. 2021. "Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy" Cancers 13, no. 19: 4846.
https://doi.org/10.3390/cancers13194846
APA Style
Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A.-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L.,
... Pøhl, M.
(2021). Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy. Cancers, 13(19), 4846.
https://doi.org/10.3390/cancers13194846
